Lead Product(s) : Fosciclopirox
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CicloMed LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPX-POM (fosciclopirox) is a patented, parentally administered prodrug of a commercially available topical antifungal agent, ciclopirox. It is under phase 1/2 clinical development for the treatment of bladder cancer and Acute Myeloid Leukemia (AML).
Product Name : CPX-POM
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Fosciclopirox
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CicloMed LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosciclopirox
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Fosciclopirox
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosciclopirox,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CicloMed LLC
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of co-development agreement, CicloMed holds the responsibility for executing clinical trial operations while Notable is focused on optimizing Notable’s predictive precision medicine platform with the goal of assessing patient responsive...
Product Name : CPX-POM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2021
Lead Product(s) : Fosciclopirox,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CicloMed LLC
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fosciclopirox
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Cmed Clinical Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2017
Lead Product(s) : Fosciclopirox
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Cmed Clinical Services
Deal Size : Inapplicable
Deal Type : Inapplicable